ArticlePloS one2025
Characteristics and actions in high-risk COPD in unstable patients: The EPOCONSUL audit.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study.Pulmonary therapy · 2026Article
- Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study.Advances in therapy · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the clinical characteristics of high-risk COPD patients considered not stable for having had moderate or severe exacerbations of COPD in the three months prior to the audited review visit based on information extracted from the medical record documenting health interactions prior to the visit, and to analyse the therapeutic measures adopted at the follow-up visit.
methodsThis analysis used data from the EPOCONSUL audit, which evaluated outpatient care provided to COPD patients in respiratory clinics in Spain. This analysis included patients with a high-risk level of COPD and assessed patient non-stability at the audited visit defined based on moderate or severe exacerbations in the last three months that were reported at the follow-up visit. Results: 2008 high-risk patients were analysed. 30.1% of patients were considered unstable at visit. Factors associated with non-stability are dyspnoea (MRC-m) ≥2 (OR 1.5, 95% CI 1.18-1.92; p = 0.001), chronic bronchitis criteria (OR 1.61, 95% CI 1.15-2.25; p = 0.005), use of inhaled triple therapy (OR 1. 31, 95% CI 1.06-1.61; p = 0.010), use of oral therapies for COPD (OR 1.68, 95% CI 1.23-2.28, p = 0.001), use of long-term oxygen therapy (OR 1.36, 95% CI 1.07-1.73, p = 0.010), no follow-up in a specialist COPD clinic (OR 1.44, 95% CI 1.11-1.87, p = 0.006). In 10.1% of the patients considered not stable, because at the medical visit they were referred to have had moderate or severe exacerbations in the last three months, no action was taken at the visit and in 56% there was no change in COPD pharmacological treatment. Triple therapy was the most commonly prescribed therapy (68% in non-stable patients). Twenty-five percent of patients on triple inhaled therapy are also prescribed oral therapy.
conclusionsOne third of patients with high-risk COPD report exacerbations requiring treatment with antibiotics and/or systemic corticosteroids in the previous three months at the medical visit; and in more than half of these patients no changes in pharmacological treatment are made at the visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.